Q-omics provides the consensus-scored ZFYVE27 profile across patient tissues and cancer cell-line models. ZFYVE27 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFYVE27 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZFYVE27 RNA expression shows 19,819 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ZFYVE27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFYVE27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFYVE27 survival associations across molecular data types. ZFYVE27 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFYVE27 RNA expression–survival associations across cancer types. High ZFYVE27 expression shows unfavorable associations in KIRC, COAD, ACC and HNSC, but favorable associations in BLCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFYVE27 RNA expression.
This table summarizes ZFYVE27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZFYVE27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFYVE27 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, STAD, CHOL and KIRC. The HNSC box plot shows higher ZFYVE27 RNA expression in tumor versus normal tissue (log2 FC = +0.739, t-test p < 0.001).
This table shows molecular features associated with ZFYVE27 in patient tissues and cancer cell lines. In patient samples, ZFYVE27 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFYVE27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
